Kenvue becomes a fully independent company following final separation from Johnson & Johnson A new view of care

Johnson & Johnson’s consumer health business Kenvue priced its IPO at $22 per share Wednesday, toward the high end of its stated range, in an upsized deal that would bring in about $3.8 billion. One thing investors will like about the stock is that Kenvue stated in its prospectus that it expects to pay a quarterly cash dividend of $0.20 per share later this year. Assuming that is the case and the company pays every quarter, that would result in a yield of around 3.1% based on a share price of $26, which would be higher than the S&P 500 average of 1.7%.

J&J faces thousands of allegations that its talc baby powder and other talc products caused cancer. Some of those products fall under the company’s consumer health business. The one risk that concerns me the most is that investors still face potential liability related to talc-based products the company sold. Usage of the new company logo and the world’s highest government bond interest rates corporate brand identity will be effective upon completion of the planned separation.

Kenvue is the world’s largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand, Johnson’s®, Listerine®, Neutrogena®, and Tylenol®, are science-backed and recommended by healthcare professionals around the world. At Kenvue, we believe in the extraordinary power of everyday care, and our teams work every day to put that power in consumers’ hands and earn a place in their hearts and homes.

Unsatisfied with the progress so far, management said it would raise its marketing outlay even further this August. Now, marketing expenses are expected to rise by 20%, or $400 million this year. Shares of Kenvue (KVUE -0.04%) got a nice bounce on Monday, Oct. 21, thanks to Starboard Value.

Essential health

The Company cautions you not to place undue reliance on these non-GAAP financial measures, but instead to consider them with the most Virtual reality stocks directly comparable U.S. These non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation. These non-GAAP financial measures should be considered supplements to, not substitutes for, or superior to, the corresponding financial measures calculated in accordance with U.S. © 2024 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions.

The company had a trading volume of 10,506,181 shares, compared to its average volume of 15,326,525. The firm has a market cap of $46.17 billion, a price-to-earnings ratio of 43.78, a PEG ratio of 2.19 and a beta of 1.36. The business’s 50-day simple moving average is $22.84 and its 200 day simple moving average is $20.86. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. Over a century ago, Johnson & Johnson practically invented the consumer healthcare industry with products like Band-Aids and Listerine. With more recent brands like Tylenol and Neutrogena to promote, Starboard thinks the company should spend more on marketing, making some strong arguments.

Financial Calendars

1. The Company believes these measures help improve investors’ ability to understand the Company’s operating performance and makes it easier to compare the Company’s results with other companies.
2. Unsatisfied with the progress so far, management said it would raise its marketing outlay even further this August.
3. Kenvue is the maker of iconic brands familiar to both investors and the broader public, such as Aveeno, Band-Aid, Listerine, Neutrogena, Tylenol and J&J’s namesake baby powder and shampoo.
4. From best practices to best-in-class products, we learn, test, partner and optimize.
5. A number of equities research analysts have recently issued reports on KVUE shares.

Haleon is up more than 20% for the year, while Procter & Gamble’s stock is up nearly 17%. Shares surged about 5% in Monday trading on the news, which was first reported by The Wall Street Journal. Overall, Kenvue said 2022 sales were “well balanced” across the company’s three business divisions.

Kenvue presents new data about osteoarthritis treatment trends at PAINWeek Conference 2024

Johnson & Johnson completed its separation from Kenvue in August 2023, though the pharmaceutical giant still holds a stake in the new company. Despite the recent bump, Kenvue stock has fallen by about 15% since it was spun off from Johnson & Johnson last May. The loss is extra upsetting because the benchmark S&P 500 index has risen about 43% over the same time frame. But Kenvue said in the filing that “such indemnity may not be sufficient” to protect the new company against the full amount of liabilities. Kenvue rounded up several J&J executives to helm the company, according to the filing. Kenvue noted that its global footprint is “well balanced geographically,” with roughly half of 2022 net sales coming from outside North America.

By the numbers: How Kenvue’s Healthy Lives Mission is making an impact

But how to start a forex brokerage in 2023 step by step beyond our portfolio of iconic brands, Kenvue is built on a foundation of core values, which fuel our 20,000+ global team members every day. Kenvue has some strong brands in its portfolio, decent financials, and even plans to pay a dividend. It isn’t an attractive option for growth investors, and while the dividend could be relatively high out of the gate, the risk the company faces with respect to talc liabilities negates those positives for me. Investors who are interested in owning the stock may want to see how the company does in its first few quarters before buying shares of the business to see how it performs, as there’s certainly no rush to buy it now. The third quarter Effective tax rate was 33.6% vs 25.1% in the prior year period. The Adjusted effective tax rate1 was 28.9% vs. 25.3% in the prior year period.